Novocure-Zai announce MAA approval for Optune to treat GBM patients

Date: 2020-05-15   Author: Saipriya Iyer  Category: #news

Novocure-Zai announce MAA approval for Optune to treat GBM patients

Novocure and Zai Lab Ltd. have recently announced the MAA (Marketing Authorization Application) approval from the China NMPA (National Medical Products Administration). The approval has been given for the use of Optune, in combination with temozolomide, to treat newly diagnosed GBM (glioblastoma) patients. It will also be used as a monotherapy for patients suffering from recurrent GBM. Optune is the 1st treatment for GBM that has been approved in over 15 years in China.

According to Dr. Samantha Du, Zai Lab’s CEO, Chairperson, and Founder, the recent approval is a significant treatment advancement for GBM patients in China and an important milestone for the company. Optune has previously been granted with the Innovative Medical Device Designation. It highlights the importance and differentiation of this novel treatment for patients with GBM. The company appreciates NMPA for this thorough and rapid assessment of the application of Optune, which will help serve high unmet medical needs. Dr. Du further stated that the company is looking forward to working with Novocure, to leverage Tumor Treating Fields and treat several cancer indications, including GBM.

William Doyle, Executive Chairman of Novocure, stated that the company is focusing on the commercialization and development of Tumor Treating Fields to increase the survival rate of several aggressive cancers. He also expressed appreciation towards their partner, Zai Lab, for collectively working to obtain Optune approval in Greater China.

Tumor Treating Fields therapy is delivered by Optune to the tumor region. It has been used to treat over 15,000 GBM patients to date, globally. The therapy has been approved by the FDA for the treatment of MPM (malignant pleural mesothelioma), which is expected to be the next Marketing Authorization Application filed with the China NMPA. It is also under Phase 3 pivotal trials to treat ovarian cancer, pancreatic cancer, non-small cell lung cancer, and brain metastases, and in Phase 2 pilot trials to treat gastric cancer and liver cancer. In China, over 1.5 million patients are diagnosed with gastric, ovarian, non-small cell lung, and pancreatic cancers, collectively in a year.

Source credit:https://www.businesswire.com/news/home/20200513005458/en/China-NMPA-Approves-Optune%C2%AE-Treatment-Newly-Diagnosed



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Cardiac Resynchronization Therapy (CRT) Devices Market to 2026 - Growth Trends and Revenue Statistics

Author: Rahul Varpe

A highly analytical qualitative as well as quantitative evaluation of the Cardiac Resynchronization Therapy (CRT) Devices Market has been covered in this report. The study evaluates the myriad aspects of this industry by taking into consideration ...


Medical Products Market Growth Rate, Revenue and Demand Analysis to 2026

Author: Rahul Varpe

An extremely definite evaluation of the Medical Products Market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have ...


Intensive Care Beds Market - Geography Insights and Opportunity Analysis to 2026

Author: Rahul Varpe

The latest study provides an in-depth analysis of the Intensive Care Beds Market focusing on various market definitions, segmentations, sub-segmentations, products, as well as applications. The report further details of the competitive landscape &...